Serum triglyceride concentration in dogs with epilepsy treated with phenobarbital or with phenobarbital and bromide

Abstract

Objective - To compare serum triglyceride concentrations obtained after food had been withheld (ie, fasting concentrations) in dogs with epilepsy that had been treated long term (≥ 3 months) with phenobarbital or with phenobarbital and potassium bromide with concentrations in healthy control dogs. Design - Cross-sectional study. Animals - 57 epileptic dogs that had been treated with phenobarbital (n = 28) or with phenobarbital and bromide (29) and 57 healthy, untreated control dogs matched on the basis of age, breed, sex, neuter status, and body condition score. Procedures - Blood samples were collected after food had been withheld for at least 12 hours, and serum biochemical and lipid concentrations were determined. Oral fat tolerance tests were performed in 15 control dogs and 9 dogs with epilepsy treated with phenobarbital alone. Results - 19 of the 57 (33%) epileptic dogs had fasting serum triglyceride concentrations greater than the upper reference limit. Nine (16%) dogs had a history of pancreatitis, and 5 of the 9 had high fasting serum triglyceride concentrations at the time of the study. A significant relationship was found between body condition score and fasting serum triglyceride concentration in all dogs, but serum triglyceride concentration was not significantly associated with phenobarbital dosage or serum phenobarbital concentration. Conclusions and Clinical Relevance - Results suggested that dogs treated long term with phenobarbital or with phenobarbital and bromide may develop hypertriglyceridemia. Fasting serum triglyceride concentration should be periodically monitored in dogs treated with phenobarbital because hypertriglyceridemia is a risk factor for pancreatitis.